Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
1995/01/01 by M. L. L. Prevoo, M.L.L. Prevoo, Martin A. van't Hof +8 · 6,254 citations
Medicine · #Alternative medicine #Arthritis #Clinical psychology #Construct validity #Disease #Internal medicine #Joint disease #Medicine #Osteoarthritis #Osteoarthritis Treatment and Mechanisms #Pathology #Physical therapy #Psychometrics #Rheumatoid Arthritis Research and Therapies #Rheumatoid arthritis #Spondyloarthritis Studies and Treatments
paper · open access · doi:10.1002/art.1780380107
published in Arthritis & Rheumatism 38(1), 44-48 (Wiley)
openalex publication_date 1995/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
Abstract
OBJECTIVE: The development and validation of Modified Disease Activity Scores (DAS) that include different 28-joint counts. METHODS: These scores were developed by canonical discriminant analyses and validated for criterion, correlational, and construct validity. The influence of disease duration on the composition of the DAS was also investigated. RESULTS: No influence of disease duration was found. The Modified DAS that included 28-joint counts were able to discriminate between high and low disease activity (as indicated by clinical decisions of rheumatologists). CONCLUSION: The Modified DAS are as valid as disease activity scores that include more comprehensive joint counts.
Cited by
- Inequities in access to biologic and synthetic DMARDs across 46 European countries
- Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis
- Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?
- Sialic acid–binding Ig‐like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus
- Association of HLA-DRB1 alleles with rheumatoid arthritis in Split-Dalmatia County in southern Croatia
- Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis
- Evolution of the Outer Galactic Disk via Chemical Abundance Patterns
- Chronic Inflammatory Disease Is an Independent Risk Factor for Coronary Flow Velocity Reserve Impairment Unrelated to the Processes of Coronary Artery Calcium Deposition
- A Longterm Prospective Real-life Experience with Leflunomide in Juvenile Idiopathic Arthritis
- Prevalence and clinical correlates of pruritus in patients with systemic sclerosis
- Validity and contributions to pain from the central aspects of pain questionnaire in rheumatoid arthritis
- Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis
- Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: a systematic review following COSMIN guidelines
- Differential response of tissue engineered skeletal muscle from rheumatoid arthritis patients and healthy controls
- Disease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort
- Tryptase is a candidate autoantigen in rheumatoid arthritis
- Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis
- Assessing the content validity of a Patient Reported Outcome Measure item pool for Rheumatoid Arthritis Disease Activity using cognitive interviews
- Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls
- Osteoporosis in psoriatic arthritis: Is there any?
- Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides
- Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
- Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis
- Golimumab for rheumatoid arthritis
- Biologics for rheumatoid arthritis: an overview of Cochrane reviews
- Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity
- Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis
- Rheumatoid arthritis
- Rituximab for rheumatoid arthritis
- Extracellular calreticulin is present in the joints of patients with rheumatoid arthritis and inhibits FasL (CD95L)–mediated apoptosis of T cells
- Tocilizumab for rheumatoid arthritis
- A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
- Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
- Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
- Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- Target Trial Emulation to Incorporate Real-World Data in the Estimation of the Clinical and Cost-Effectiveness of Biologic Treatment
- Patient-Reported Outcomes in Psoriatic Arthritis
- Rheumatoid arthritis [wikipedia]
- Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. [europepmc]
- Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. [europepmc]
- Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. [europepmc]
- Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. [europepmc]
- Sex differences in rheumatoid arthritis: more than meets the eye... [europepmc]
- Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. [europepmc]
- Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. [europepmc]
- Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis. [europepmc]
- American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. [europepmc]
- Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. [europepmc]
- Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. [europepmc]
- Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. [europepmc]
- Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. [europepmc]
- Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. [europepmc]
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. [europepmc]
- Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. [europepmc]
- EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. [europepmc]
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. [europepmc]
- Sinomenine Inhibits the Progression of Rheumatoid Arthritis by Regulating the Secretion of Inflammatory Cytokines and Monocyte/Macrophage Subsets. [europepmc]
- Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study. [europepmc]
- Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. [europepmc]
- Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. [europepmc]
- Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. [europepmc]
- Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity. [europepmc]
- Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. [europepmc]
Related